Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy.

Saneja A, Dubey RD, Alam N, Khare V, Gupta PN.

Curr Cancer Drug Targets. 2014;14(5):419-33. Review.

PMID:
24720364
2.

Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance.

Saneja A, Khare V, Alam N, Dubey RD, Gupta PN.

Expert Opin Drug Deliv. 2014 Jan;11(1):121-38. doi: 10.1517/17425247.2014.865014. Epub 2013 Dec 3. Review.

PMID:
24295039
3.

Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation.

Bansal T, Akhtar N, Jaggi M, Khar RK, Talegaonkar S.

Drug Discov Today. 2009 Nov;14(21-22):1067-74. doi: 10.1016/j.drudis.2009.07.010. Epub 2009 Aug 6. Review.

PMID:
19647803
4.

Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy.

Bansal T, Jaggi M, Khar RK, Talegaonkar S.

J Pharm Pharm Sci. 2009;12(1):46-78.

5.
7.
9.

Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?

Callaghan R, Luk F, Bebawy M.

Drug Metab Dispos. 2014 Apr;42(4):623-31. doi: 10.1124/dmd.113.056176. Epub 2014 Feb 3. Review.

10.

Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities.

Kirtane AR, Kalscheuer SM, Panyam J.

Adv Drug Deliv Rev. 2013 Nov;65(13-14):1731-47. doi: 10.1016/j.addr.2013.09.001. Epub 2013 Sep 10. Review.

11.

Nano-based strategies to overcome p-glycoprotein-mediated drug resistance.

Niazi M, Zakeri-Milani P, Najafi Hajivar S, Soleymani Goloujeh M, Ghobakhlou N, Shahbazi Mojarrad J, Valizadeh H.

Expert Opin Drug Metab Toxicol. 2016 Sep;12(9):1021-33. doi: 10.1080/17425255.2016.1196186. Epub 2016 Jun 13. Review.

PMID:
27267126
12.

Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.

Nobili S, Landini I, Mazzei T, Mini E.

Med Res Rev. 2012 Nov;32(6):1220-62. doi: 10.1002/med.20239. Epub 2011 Mar 3. Review.

PMID:
21374643
13.

Therapeutic potential of nanocarrier for overcoming to P-glycoprotein.

Kaur V, Garg T, Rath G, Goyal AK.

J Drug Target. 2014 Dec;22(10):859-70. doi: 10.3109/1061186X.2014.947295. Epub 2014 Aug 7. Review.

PMID:
25101945
14.

P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.

Breier A, Barancík M, Sulová Z, Uhrík B.

Curr Cancer Drug Targets. 2005 Sep;5(6):457-68. Review.

PMID:
16178819
15.

Pharmacological strategies for overcoming multidrug resistance.

Nobili S, Landini I, Giglioni B, Mini E.

Curr Drug Targets. 2006 Jul;7(7):861-79. Review.

PMID:
16842217
16.

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.

Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G.

Cancer Chemother Pharmacol. 1997;40 Suppl:S13-9. Review.

PMID:
9272128
17.

Mechanisms of P-glycoprotein alteration during anticancer treatment: role in the pharmacokinetic and pharmacological effects of various substrate drugs.

Kobori T, Harada S, Nakamoto K, Tokuyama S.

J Pharmacol Sci. 2014;125(3):242-54. Epub 2014 Jul 2. Review.

18.

Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance.

Sarisozen C, Vural I, Levchenko T, Hincal AA, Torchilin VP.

Drug Deliv. 2012 Nov;19(8):363-70. doi: 10.3109/10717544.2012.724473. Epub 2012 Oct 3.

PMID:
23030458
19.

New insight into p-glycoprotein as a drug target.

Breier A, Gibalova L, Seres M, Barancik M, Sulova Z.

Anticancer Agents Med Chem. 2013 Jan;13(1):159-70. Review.

PMID:
22931413
20.

Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.

Minocha M, Khurana V, Qin B, Pal D, Mitra AK.

Int J Pharm. 2012 Sep 15;434(1-2):306-14. doi: 10.1016/j.ijpharm.2012.05.028. Epub 2012 May 23.

Supplemental Content

Support Center